BR112021026408A2 - Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 - Google Patents

Receptores de célula t que reconhecem a mutação r175h ou y220c em p53

Info

Publication number
BR112021026408A2
BR112021026408A2 BR112021026408A BR112021026408A BR112021026408A2 BR 112021026408 A2 BR112021026408 A2 BR 112021026408A2 BR 112021026408 A BR112021026408 A BR 112021026408A BR 112021026408 A BR112021026408 A BR 112021026408A BR 112021026408 A2 BR112021026408 A2 BR 112021026408A2
Authority
BR
Brazil
Prior art keywords
cell receptors
mutation
recognize
present
mammal
Prior art date
Application number
BR112021026408A
Other languages
English (en)
Portuguese (pt)
Inventor
Anna Pasetto
C Deniger Drew
Parisa Malekzadeh
A Rosenberg Steven
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112021026408A2 publication Critical patent/BR112021026408A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
BR112021026408A 2019-06-27 2020-06-26 Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 BR112021026408A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867619P 2019-06-27 2019-06-27
PCT/US2020/039785 WO2020264269A1 (en) 2019-06-27 2020-06-26 T cell receptors recognizing r175h or y220c mutation in p53

Publications (1)

Publication Number Publication Date
BR112021026408A2 true BR112021026408A2 (pt) 2022-02-08

Family

ID=71662353

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026408A BR112021026408A2 (pt) 2019-06-27 2020-06-26 Receptores de célula t que reconhecem a mutação r175h ou y220c em p53

Country Status (11)

Country Link
US (1) US12479902B2 (enExample)
EP (1) EP3990481A1 (enExample)
JP (2) JP7635165B2 (enExample)
KR (1) KR20220047969A (enExample)
CN (1) CN114341171A (enExample)
AU (1) AU2020308004B2 (enExample)
BR (1) BR112021026408A2 (enExample)
CA (1) CA3144070A1 (enExample)
MX (1) MX2021015877A (enExample)
TW (2) TW202525841A (enExample)
WO (1) WO2020264269A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019077062A1 (en) * 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022232599A1 (en) * 2021-04-30 2022-11-03 Regents Of The University Of Minnesota Mesothelin-specific t cell receptors and methods of using same
WO2022235577A2 (en) * 2021-05-03 2022-11-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1
JP2024517884A (ja) * 2021-05-07 2024-04-23 アメリカ合衆国 ｐ５３におけるＣ１３５Ｙ、Ｒ１７５Ｈ又はＭ２３７Ｉ変異を認識するＴ細胞受容体
JP2024540197A (ja) * 2021-10-29 2024-10-31 ホウ，ヤフェイ Ｐ５３におけるｒ１７５ｈ変異を認識するｔ細胞受容体およびその用途
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
WO2024076692A1 (en) * 2022-10-05 2024-04-11 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as p53 acetylators
WO2024163371A1 (en) * 2023-01-30 2024-08-08 Fred Hutchinson Cancer Center Binding proteins specific for mutant p53 and uses thereof
WO2024206274A2 (en) 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2024220520A2 (en) * 2023-04-21 2024-10-24 Board Of Regents, The University Of Texas System T-cell receptors targeting her2 and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
MX375379B (es) 2014-05-29 2025-03-06 Us Health Receptores de celulas t anti - papilomavirus 16 e7 humano.
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
CN107748893A (zh) * 2017-09-29 2018-03-02 阿里巴巴集团控股有限公司 提升车辆定损图像识别结果的方法、装置及服务器
SG11202002635RA (en) 2017-09-29 2020-04-29 The United States Of America As Represented By The Secretary Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
WO2019067243A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T CELL RECEPTORS RECOGNIZING P53 MUTE
JP2024517884A (ja) 2021-05-07 2024-04-23 アメリカ合衆国 ｐ５３におけるＣ１３５Ｙ、Ｒ１７５Ｈ又はＭ２３７Ｉ変異を認識するＴ細胞受容体
WO2024206274A2 (en) 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53

Also Published As

Publication number Publication date
WO2020264269A1 (en) 2020-12-30
JP2025081413A (ja) 2025-05-27
MX2021015877A (es) 2022-04-18
KR20220047969A (ko) 2022-04-19
EP3990481A1 (en) 2022-05-04
AU2020308004B2 (en) 2026-03-19
US12479902B2 (en) 2025-11-25
AU2020308004A1 (en) 2022-02-03
TW202108609A (zh) 2021-03-01
CA3144070A1 (en) 2020-12-30
US20220332785A1 (en) 2022-10-20
JP7635165B2 (ja) 2025-02-25
TWI908730B (zh) 2025-12-21
JP2022538148A (ja) 2022-08-31
CN114341171A (zh) 2022-04-12
TW202525841A (zh) 2025-07-01

Similar Documents

Publication Publication Date Title
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
MX2024005676A (es) Receptores de celulas t que reconocen p53 mutado.
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
MX2015003061A (es) Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
BR112022015897A2 (pt) Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v
BR112022015888A2 (pt) Receptores de células t restritos a hla classe i contra ras com mutação g12d
MX2017006865A (es) Receptores de células t de kras anti-mutado.
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BR112022016661A2 (pt) Receptores de células t restritos ao hla classe ii contra ras com mutação g12v
BR122020002402B8 (pt) Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma
CY1116413T1 (el) Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
BR112012018457A2 (pt) peptídeos melk modificados e vacinas contendo os mesmos
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
WO2022051449A3 (en) T cell receptors recognizing r273c or y220c mutations in p53
WO2021262829A3 (en) Hla class i-restricted t cell receptors against cd20
BR112015031194A2 (pt) Molécula quimérica e método para fazer a mesma, polinucleotídeo ou um conjunto de polinucleotídeos, vetor ou um conjunto de vetores, célula hospedeira, composição farmacêutica, uso dos anteriores, e método para aumentar a atividade de fviii da molécula quimérica